Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2021 08:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer

BOSTON and LONDON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to...
October 04, 2021 08:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital

BOSTON and LONDON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa” or “Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals annonce des résultats positifs de premier ordre sur une étude de preuve de concept concernant le SerpinPC chez des patients hémophiles A et B graves non traités par prophylaxie

~ Baisse de 88 % de la valeur médiane du taux de saignement annualisé (TSA) pour tous les cas de saignements, et baisse de 94 % du TSA médian pour les saignements articulaires spontanés à la plus...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals anuncia datos preliminares positivos del estudio preliminar de eficacia de SerpinPC en pacientes con hemofilia A y B grave que no están recibiendo tratamiento de profilaxis

~ 88 % de reducción en la mediana de la tasa anualizada de hemorragia (TAH) para todas las hemorragias y 94 % de reducción en la mediana de TAH para las hemorragias articulares espontáneas en la dosis...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals annuncia dati topline positivi da uno studio “proof of concept” di SerpinPC in pazienti affetti da grave emofilia A e B non in profilassi

~ Riduzione dell’88% del tasso di sanguinamento annualizzato (ABR) mediano per tutti gli emorragie e riduzione del 94% dell'ABR mediano per emorragie articolari spontanee nella dose più elevata...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals gibt positive Topline-Daten aus der Proof-of-Concept-Studie zu SerpinPC bei Patienten mit schwerer Hämophilie A und B ohne prophylaktische Behandlung bekannt

~ 88 % Reduktion der medianen annualisierten Blutungsrate (Annualized Bleeding Rate, ABR) bei allen Blutungen und 94 % Reduktion der medianen ABR bei spontanen Gelenkeinblutungen bei der höchsten...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals kondigt positieve topline-gegevens aan uit Proof-of-Concept-onderzoek van SerpinPC bij patiënten met ernstige hemofilie A en B die geen preventieve behandeling ondergaan

~ 88% reductie in mediaan jaarlijks bloedingspercentage (ABR) voor alle bloedingen en 94% reductie in mediaan ABR voor spontane gewrichtsbloedingen bij de hoogste geteste dosis ~ ~ SerpinPC werd goed...
September 13, 2021 09:51 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals объявляет о положительных данных по результатам проверочного исследования SerpinPC у пациентов с тяжелой формой гемофилии A и B, не получающих профилактического лечения

~ 88% снижение средней годовой скорости кровотечения (ABR) для всех кровотечений и 94% снижение медианы ABR для спонтанных суставных кровотечений в самой высокой испытанной дозе ~ ~ SerpinPC хорошо...
September 09, 2021 07:30 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated...
September 02, 2021 14:20 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals nimmt an der virtuellen Konferenz Morgan Stanley 19th Annual Global Healthcare Conference teil

CAMBRIDGE, Mass. und LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) gab heute bekannt, dass Saurabh Saha, M.D., Ph.D., Chief Executive Officer, am Dienstag,...